Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure

Julian Vaile, Saqib Chowdhary, Faizel Osman, Hamish Ross, Janine Fletcher, William Littler, John Coote, Jonathan Townend

Research output: Contribution to journalArticle

25 Citations (Scopus)


The objective of the present study was to determine the autonomic effects of angiotensin II (AT(1)) receptor blocker therapy in heart failure. In a randomized double-blind cross-over study, we compared the effects of candesartan and placebo on baroreflex sensitivity and on heart rate variability at rest, during stress and during 24 h monitoring. Acute effects were assessed 4 h after oral candesartan (8 mg) and chronic effects after 4 weeks of treatment (dose titrated to 16 mg daily). The study group comprised 21 patients with heart failure [mean (S.E.M.) ejection fraction 33% (1%)], in the absence of angiotensin-converting enzyme (ACE) inhibitor therapy. We found that acute candesartan was not different from placebo in its effects on blood pressure or mean RR interval. Chronic candesartan significantly reduced blood pressure [placebo, 137 (3)/82 (3) mmHg; candesartan, 121 (4)/75 (2) mmHg; P
Original languageEnglish
Pages (from-to)559-566
Number of pages8
JournalClinical Science
Issue number6
Publication statusPublished - 1 Dec 2001


  • heart rate
  • baroreflex sensitivity
  • vagus nerve
  • heart rate variability
  • angiotensin
  • heart failure


Dive into the research topics of 'Effects of angiotensin II (AT1) receptor blockade on cardiac vagal control in heart failure'. Together they form a unique fingerprint.

Cite this